Pipeline
Advancing novel precision therapeutics for serious cardiovascular diseases
Cardiovascular
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator for the treatment of HCM.
EDG-15400 is a novel oral, selective, cardiac sarcomere modulator, for the treatment of HFpEF and other diseases of diastolic dysfunction
EDG-003
Undisclosed Target
Cardiometabolic
Preclinical
Servier Acquires Our Muscular Dystrophy Program
Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.
Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.
Is a clinical trial right for you?
We are currently conducting clinical trials in severe cardiovascular diseases.
